A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

NCT05809752 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Leptomeningeal Disease
Triple Negative Breast Cancer
HER2-positive Breast Cancer

Interventions

BIOLOGICAL: Dendritic Cell Vaccine

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]